Citation:Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al 2014

From Cancer Guidelines Wiki

Citation


Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014 Dec 4;371(23):2167-77 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/25470694.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?
What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?
What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?
Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?
Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC
  3. What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?